https://travere.com/
Travere Therapeutics | In Rare For Life
Apr 14, 2026 - Travere Therapeutics is a biopharmaceutical company whose mission is to identify, develop and deliver life-changing therapies to people living with rare...
travere therapeuticsrarelife
https://www.biospace.com/retrophin-announces-corporate-name-change-to-travere-therapeutics-inc
Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc. - BioSpace
Nov 16, 2020 - Retrophin Inc., (NASDAQ: RTRX) today announced that the Company has changed its global corporate name to Travere Therapeutics, Inc. This new name reflects the...
corporate name changetravere therapeuticsretrophinannouncesinc
https://www.benzinga.com/insights/analyst-ratings/25/04/44593072/the-analyst-verdict-travere-therapeutics-in-the-eyes-of-7-experts
The Analyst Verdict: Travere Therapeutics In The Eyes Of 7 Experts - Travere Therapeutics...
the analysttravere therapeuticsof 7verdicteyes
https://www.globenewswire.com/news-release/2025/03/17/3043582/0/en/Travere-Therapeutics-Submits-sNDA-to-FDA-for-Approval-of-FILSPARI-sparsentan-for-the-Treatment-of-FSGS.html
Travere Therapeutics Submits sNDA to FDA for Approval of
Travere announces sNDA submission to FDA based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS, a rare kidney condition....
travere therapeuticssubmitssndafdaapproval
https://www.marketscreener.com/quote/stock/TRAVERE-THERAPEUTICS-INC-15458731/
Travere Therapeutics, Inc. Stock (TVTX) - Quote Nasdaq- MarketScreener
Travere Therapeutics, Inc. (TVTX:NASDAQ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Travere Therapeutics, Inc. |...
travere therapeuticsincstockquotenasdaq
https://finviz.com/quote?t=TVTX
TVTX - Travere Therapeutics Inc Stock Price and Quote
TVTX - Travere Therapeutics Inc - Stock screener for investors and traders, financial visualizations.
travere therapeuticsstock priceincquote
https://www.fool.com/investing/2021/08/16/heres-why-travere-therapeutics-stock-is-climbing-t/
Here's Why Travere Therapeutics Stock Is Climbing Today | The Motley Fool
Aug 16, 2021 - Investors are cheering positive phase 3 trial results with sparsentan that suggest it could become an important new treatment for a rare kidney disease.
here stravere therapeutics
https://www.macrotrends.net/stocks/charts/TVTX/travere-therapeutics/total-assets
Travere Therapeutics Total Assets 2012-2026 | TVTX | MacroTrends
Travere Therapeutics total assets from 2012 to 2026. Total assets can be defined as the sum of all assets on a company's balance sheet.
travere therapeuticstotal assets20122026macrotrends
https://www.globenewswire.com/fr/news-release/2021/11/02/2325894/0/en/travere-therapeutics-to-present-abstracts-at-american-society-of-nephrology-kidney-week-2021.html
Travere Therapeutics to Present Abstracts at American
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will...
travere therapeuticspresentabstractsamerican
https://www.globenewswire.com/fr/news-release/2024/10/14/2962853/0/en/travere-therapeutics-to-present-abstracts-at-american-society-of-nephrology-asn-kidney-week-2024.html
Travere Therapeutics to Present Abstracts at American
Travere Therapeutics will present 11 abstracts, including one late-breaking abstract, at the upcoming ASN Kidney Week 2024 in San Diego....
travere therapeuticspresentabstractsamerican
https://www.sofi.com/invest/stock/TVTX/
Buy Travere Therapeutics Stock - TVTX Stock Price, Quote & News | SoFi
See real time price charts for TVTX stock, historical data, and recent news. Buy TVTX stock online with no commission fees.
travere therapeuticsprice quotebuystocknews
https://www.globenewswire.com/fr/news-release/2024/10/26/2969690/0/en/travere-therapeutics-presents-data-reinforcing-clinical-benefit-of-filspari-sparsentan-in-igan-and-late-breaking-presentation-in-fsgs-at-asn-kidney-week-2024.html
Travere Therapeutics Presents Data Reinforcing Clinical
Travere presents data on FILSPARI (sparsentan) in IgAN and FSGS at ASN Kidney Week 2024....
travere therapeuticspresentsdatareinforcingclinical
https://www.finanznachrichten.de/nachrichten-2026-04/68230968-weekly-buzz-fda-okays-travere-therapeutics-royal-philips-rejects-replimune-american-industrial-partners-snaps-up-avanos-medical-pds-biotechnology-020.htm
Weekly Buzz: FDA Okays Travere Therapeutics, Royal Philips; Rejects Replimune; American Industrial...
INDIANAPOLIS (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., Taiwan, and Europe, alongside FDA rejections,...
weekly buzztravere therapeutics
https://www.macrotrends.net/stocks/charts/TVTX/travere-therapeutics/stock-splits
Travere Therapeutics - 15 Year Stock Split History | TVTX | MacroTrends
Stock split history for Travere Therapeutics since 2011. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please...
stock split historytravere therapeutics15 yearmacrotrends
https://www.biospace.com/travere-therapeutics-announces-european-commission-has-granted-orphan-designation-to-sparsentan-for-the-treatment-of-iga-nephropathy
Travere Therapeutics Announces European Commission Has Granted Orphan Designation to Sparsentan for...
Feb 18, 2021 - Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the European Commission (EC) has granted orphan designation to sparsentan for the treatment of IgA...
travere therapeuticseuropean commission
https://www.financialcontent.com/article/publisher/Travere%20Therapeutics%2C%20Inc.
Articles from Travere Therapeutics, Inc. | FinancialContent
View all of the latest articles from Travere Therapeutics, Inc.
travere therapeuticsarticlesinc
https://www.benzinga.com/news/earnings/21/05/21305158/mid-afternoon-market-update-build-a-bear-rises-after-q1-results-travere-therapeutics-shares-drop
Mid-Afternoon Market Update: Build-A-Bear Rises After Q1 Results; Travere Therapeutics Shares Drop...
https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-travere-therapeutics-adma-biologics-surgalign-cti-biopharma-or-opgen-301355776.html
Thinking about buying stock in Travere Therapeutics, ADMA Biologics, Surgalign, CTI BioPharma, or...
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TVTX, ADMA, SRGA, CTIC, and OPGN. To see how InvestorsObserver's proprietary scoring...
https://theorg.com/org/travere-therapeutics/org-chart/angela-giannantonio
Angela Giannantonio - Senior Vice President Global Human Resources at Travere Therapeutics | The Org
Angela Giannantonio is a senior vice president and member of the executive team at Travere Therapeutics.
senior vice presidentglobal human resources
https://ground.news/article/avanos-medical-inc-agrees-to-be-acquired-by-american-industrial-partners-for-approximately-1272-billion
Avanos Medical, Travere Therapeutics, Globalstar And Other Big Stocks Moving Higher On Tuesday
Apr 15, 2026 - U.S. stocks were higher, with the Dow Jones index gaining over 200 points on Tuesday. Shares of Avanos Medical Inc (NYSE:AVNS) rose sharply following the...
https://www.biospace.com/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-may-11-2023
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 11, 2023...
May 12, 2023 - Travere Therapeutics, Inc. announced that on May 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to six new...
https://www.biospace.com/press-releases/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
https://www.biospace.com/travere-therapeutics-to-present-at-national-kidney-foundation-spring-clinical-meetings-and-the-61st-european-renal-association-congress
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st...
May 10, 2024 - Travere Therapeutics, Inc., announced that the Company will present nine abstracts in rare kidney disease at the National Kidney Foundation Spring Clinical...
https://theorg.com/org/travere-therapeutics/org-chart/christian-ellereit
Christian Ellereit - Head Of Finance & Operations Europe at Travere Therapeutics | The Org
Christian Ellereit has a strong background in finance and operations, primarily in the pharmaceutical and healthcare industries.
head of finance